Advanced Search

Technical Analysis for RVMD - Revolution Medicines, Inc.

Grade Last Price % Change Price Change
grade B 21.99 -2.18% -0.49
RVMD closed down 10.86 percent on Friday, March 27, 2020, on 37 percent of normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical RVMD trend table...
Date Alert Name Type % Chg
Wide Bands Range Expansion -2.18%
20 DMA Resistance Bearish -12.81%
Wide Bands Range Expansion -12.81%
Outside Day Range Expansion -15.29%
Wide Bands Range Expansion -15.29%
NR7 Range Contraction -9.69%
Wide Bands Range Expansion -9.69%
Multiple of Ten Bullish Other -3.04%
Wide Bands Range Expansion -3.04%
Shooting Star Candlestick Bearish -5.38%
Older EOD signals for RVMD ...
View Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
RVMD Chart by TradingView
Basic chart:

Profile

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
Medicine Cancer Clinical Medicine Pharmacology Cancer Treatment Medical Terminology Signal Transduction Mtor

Is RVMD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Mar 18 Revolution Medicines nabs new patent in U.S.
Mar 18 Revolution Medicines Announces Issuance of U.S. Patent Covering Compositions of Matter for its Clinical-Stage SHP2 Inhibitor Program
Mar 13 88 Stocks Moving In Friday's Mid-Day Session
Mar 9 New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute
Mar 9 RBC trims view on Gilead in premarket analyst action
Mar 8 The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
Mar 7 Stocks To Watch: Fading The Fear
Mar 5 The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19
Mar 4 Revolution Should Be On Your Radar; 'Undruggable Targets' Now Potentially Druggable
Feb 18 Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
See more RVMD news...

Indicators

Indicator Value
52 Week High 37.08
52 Week Low 17.345
Average Volume 529,866
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 26.63
10-Day Moving Average 22.71
Average True Range 3.86
ADX 17.71
+DI 24.34
-DI 17.04
Chandelier Exit (Long, 3 ATRs ) 25.49
Chandelier Exit (Short, 3 ATRs ) 28.93
Upper Bollinger Band 36.18
Lower Bollinger Band 17.08
Percent B (%b) 0.28
BandWidth 71.73
MACD Line -2.70
MACD Signal Line -2.75
MACD Histogram 0.0484
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 26.74
Resistance 3 (R3) 27.20 26.25 26.03
Resistance 2 (R2) 26.25 25.16 26.01 25.79
Resistance 1 (R1) 24.36 24.49 23.89 23.90 25.56
Pivot Point 23.41 23.41 23.17 23.18 23.41
Support 1 (S1) 21.52 22.32 21.05 21.06 19.40
Support 2 (S2) 20.57 21.65 20.34 19.17
Support 3 (S3) 18.68 20.57 18.93
Support 4 (S4) 18.22